List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/370303/publications.pdf Version: 2024-02-01



Κλάξι Δονικλ

#	Article	IF	CITATIONS
1	Rare PSAP Variants and Possible Interaction with GBA in REM Sleep Behavior Disorder. Journal of Parkinson's Disease, 2022, 12, 333-340.	2.8	3
2	Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurology, The, 2022, 21, 53-65.	10.2	37
3	Risk Factors for Phenoconversion in <scp>Rapid Eye Movement</scp> Sleep Behavior Disorder. Annals of Neurology, 2022, 91, 404-416.	5.3	27
4	Increased Transferrin Sialylation Predicts Phenoconversion in Isolated REM Sleep Behavior Disorder. Movement Disorders, 2022, , .	3.9	1
5	Idiopathic Hypersomnia: Historical Account, Critical Review of Current Tests and Criteria, Diagnostic Evaluation in the Absence of Biological Markers and Robust Electrophysiological Diagnostic Criteria. Nature and Science of Sleep, 2022, Volume 14, 311-322.	2.7	6
6	Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy. Nature and Science of Sleep, 2022, Volume 14, 531-546.	2.7	3
7	Data-Driven Phenotyping of Central Disorders of Hypersomnolence With Unsupervised Clustering. Neurology, 2022, 98, .	1.1	17
8	Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications. CNS Drugs, 2022, 36, 633-647.	5.9	7
9	Subjective and polysomnographic evaluation of sleep in mitochondrial optic neuropathies. Journal of Sleep Research, 2021, 30, e13051.	3.2	5
10	Comprehensive Analysis of Familial Parkinsonism Genes in Rapid‣yeâ€Movement Sleep Behavior Disorder. Movement Disorders, 2021, 36, 235-240.	3.9	11
11	Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate) Tj ETQq1 1 narcolepsy with cataplexy. Sleep, 2021, 44, .	0.784314 1.1	rgBT /Overlo 39
12	Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain, 2021, 144, 278-287.	7.6	68
13	New 2013 incidence peak in childhood narcolepsy: more than vaccination?. Sleep, 2021, 44, .	1.1	11
14	Idiopathic hypersomnia: a homogeneous or heterogeneous disease?. Sleep Medicine, 2021, 80, 86-91.	1.6	17
15	Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease. Annals of Neurology, 2021, 90, 62-75.	5.3	73
16	495 Efficacy of Lower-Sodium Oxybate on Idiopathic Hypersomnia, Measured by the Idiopathic Hypersomnia Severity Scale. Sleep, 2021, 44, A195-A195.	1.1	0
17	European guideline and expert statements on the management of narcolepsy in adults and children. European Journal of Neurology, 2021, 28, 2815-2830.	3.3	67
18	European guideline and expert statements on the management of narcolepsy in adults and children. Journal of Sleep Research, 2021, 30, e13387.	3.2	44

#	Article	IF	CITATIONS
19	Systematic video-analysis of motor events during REM sleep in idiopathic REM sleep behavior disorder, follow-up and DAT-SPECT. Sleep Medicine, 2021, 83, 132-144.	1.6	9
20	Reliability and Validity of the Czech Version of the Pittsburgh Sleep Quality Index in Patients with Sleep Disorders and Healthy Controls. BioMed Research International, 2021, 2021, 1-9.	1.9	6
21	Patients with REM sleep behavior disorder have higher serum levels of allantoin. Parkinsonism and Related Disorders, 2021, 90, 38-43.	2.2	2
22	Novel Associations of <i>BST1</i> and <i>LAMP3</i> With REM Sleep Behavior Disorder. Neurology, 2021, 96, e1402-e1412.	1.1	12
23	Idiopathic Hypersomnia and Depression, the Challenge for Clinicians and Researchers. Prague Medical Report, 2021, 122, 127-139.	0.8	4
24	Defining Speech Subtypes in De Novo Parkinson Disease. Neurology, 2021, 97, e2124-e2135.	1.1	33
25	Delayed sleep-wake phase disorder: Can polysomnography be useful?. Pediatric Neurology, 2021, 127, 28-31.	2.1	1
26	Dysprosody in Isolated REM Sleep Behavior Disorder with Impaired Olfaction but Intact Nigrostriatal Pathway. Movement Disorders, 2021, , .	3.9	5
27	Rare Case of Late-Onset Narcolepsy Type 1. Case Reports in Neurology, 2021, 12, 428-432.	0.7	3
28	Instrumental analysis of finger tapping reveals a novel early biomarker of parkinsonism in idiopathic rapid eye movement sleep behaviour disorder. Sleep Medicine, 2020, 75, 45-49.	1.6	12
29	0740 Quality of Life in Phase 3, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of JZP-258 in Adults with Narcolepsy with Cataplexy. Sleep, 2020, 43, A281-A282.	1.1	1
30	Comment on "Proâ€5accades Predict Cognitive Decline in Parkinson's Disease: ICICLEâ€PDâ€: Movement Disorders, 2020, 35, 522-522.	3.9	0
31	<i>GBA</i> variants in REM sleep behavior disorder. Neurology, 2020, 95, e1008-e1016.	1.1	45
32	MRI-guided voxel-based automatic semi-quantification of dopamine transporter imaging. Physica Medica, 2020, 75, 1-10.	0.7	3
33	Comparative study of the substantia nigra echogenicity and 123I-Ioflupane SPECT in patients with synucleinopathies with and without REM sleep behavior disorder. Sleep Medicine, 2020, 70, 116-123.	1.6	3
34	Fineâ€Mapping of <i>SNCA</i> in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. Annals of Neurology, 2020, 87, 584-598.	5.3	39
35	Diagnosis of central disorders of hypersomnolence: A reappraisal by European experts. Sleep Medicine Reviews, 2020, 52, 101306.	8.5	119
36	SMPD1 variants do not have a major role in rapid eye movement sleep behavior disorder. Neurobiology of Aging, 2020, 93, 142.e5-142.e7.	3.1	4

#	Article	IF	CITATIONS
37	Impact of the COVID-19 pandemic on sleep medicine in the Czech Republic and Slovakia. Ceska A Slovenska Neurologie A Neurochirurgie, 2020, 83/116, 421-423.	0.1	1
38	Polysomnographic findings in individuals over 50 years of age lacking subjective signs of sleep disturbance. Ceska A Slovenska Neurologie A Neurochirurgie, 2020, 83/116, 57-63.	0.1	7
39	Rare Case of Late-Onset Narcolepsy Type 1. Case Reports in Neurology, 2020, 12, 428-432.	0.7	0
40	Eye movements in idiopathic rapid eye movement sleep behaviour disorder: High antisaccade error rate reflects prefrontal cortex dysfunction. Journal of Sleep Research, 2019, 28, e12742.	3.2	17
41	Relations of non-motor symptoms and dopamine transporter binding in REM sleep behavior disorder. Scientific Reports, 2019, 9, 15463.	3.3	26
42	Fragmentary myoclonus in idiopathic rapid eye movement sleep behaviour disorder. Journal of Sleep Research, 2019, 28, e12819.	3.2	11
43	Prevalence of restless legs syndrome in functional movement disorders: a case–control study from the Czech Republic. BMJ Open, 2019, 9, e024236.	1.9	8
44	Simultaneous tonic and phasic REM sleep without atonia best predicts early phenoconversion to neurodegenerative disease in idiopathic REM sleep behavior disorder. Sleep, 2019, 42, .	1.1	31
45	Validation of the REM sleep behavior disorder screening questionnaire in the Czech population. BMC Neurology, 2019, 19, 110.	1.8	11
46	Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain, 2019, 142, 744-759.	7.6	636
47	Anterior hippocampus volume loss in narcolepsy with cataplexy. Journal of Sleep Research, 2019, 28, e12785.	3.2	12
48	Prospective memory impairment in idiopathic REM sleep behavior disorder. Sleep Medicine, 2019, 59, 54.	1.6	0
49	Olfactory dysfunction in a cohort of Czech patients with idiopathic REM sleep behaviour diorder. Ceska A Slovenska Neurologie A Neurochirurgie, 2019, 82/115, 415-419.	0.1	1
50	Automatic substantia nigra segmentation in neuromelanin-sensitive MRI by deep neural network in patients with prodromal and manifest synucleinopathy. Physiological Research, 2019, 68, S453-S458.	0.9	13
51	Behavioral manifestation profile in idiopathic REM sleep hebavior disorder. Ceska A Slovenska Neurologie A Neurochirurgie, 2019, 82/115, 437-441.	0.1	0
52	Prospective memory impairment in idiopathic REM sleep behavior disorder. Clinical Neuropsychologist, 2018, 32, 1019-1037.	2.3	18
53	The MSLT is Repeatable in Narcolepsy Type 1 But Not Narcolepsy Type 2: A Retrospective Patient Study. Journal of Clinical Sleep Medicine, 2018, 14, 65-74.	2.6	69
54	Modafinil Reduces Parasympathetic Activity but Does Not Influence Autonomic Reactivity to Orthostatic Load in Narcolepsy Type 1. Clinical Neuropharmacology, 2018, 41, 111-115.	0.7	1

#	Article	IF	CITATIONS
55	Smartphone Allows Capture of Speech Abnormalities Associated With High Risk of Developing Parkinson's Disease. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2018, 26, 1495-1507.	4.9	77
56	Accuracy of Rating Scales and Clinical Measures for Screening of Rapid Eye Movement Sleep Behavior Disorder and for Predicting Conversion to Parkinson's Disease and Other Synucleinopathies. Frontiers in Neurology, 2018, 9, 376.	2.4	39
57	Exploring the clinical features of narcolepsy type 1 versus narcolepsy type 2 from European Narcolepsy Network database with machine learning. Scientific Reports, 2018, 8, 10628.	3.3	36
58	Circadian rhythms of melatonin and peripheral clock gene expression in idiopathic REM sleep behavior disorder. Sleep Medicine, 2018, 52, 1-6.	1.6	43
59	Olfaction and Colour Vision: What Can They Tell Us about Parkinson's Disease?. Prague Medical Report, 2018, 119, 85-96.	0.8	9
60	Sleep Apnoea in Patients With Nocturnal Hypertension – a Multicenter Study in the Czech Republic. Physiological Research, 2018, 67, 217-231.	0.9	7
61	Patients with idiopathic REM sleep behavior disorder follow-up – phenoconversion into parkinsonian syndrome and dementia. Ceska A Slovenska Neurologie A Neurochirurgie, 2018, 81/114, 205-207.	0.1	1
62	Professor Milan Åpála, MD., PhD. – 1930–2018. Prague Medical Report, 2018, 119, 5-8.	0.8	0
63	Higher body mass index in narcolepsy with cataplexy: lifelong experience. Sleep Medicine, 2017, 32, 277.	1.6	3
64	Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2017, 16, 200-207.	10.2	306
65	Automated analysis of connected speech reveals early biomarkers of Parkinson's disease in patients with rapid eye movement sleep behaviour disorder. Scientific Reports, 2017, 7, 12.	3.3	245
66	Cardiovascular fitness in narcolepsy is inversely related to sleepiness and the number of cataplexy episodes. Sleep Medicine, 2017, 34, 7-12.	1.6	11
67	Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. Lancet Neurology, The, 2017, 16, 898-907.	10.2	191
68	Emotion stimulus processing in narcolepsy with cataplexy. Journal of Sleep Research, 2017, 26, 30-37.	3.2	5
69	Spontaneous improvement in both obstructive sleep apnea and cognitive impairment after stroke. Sleep Medicine, 2017, 32, 137-142.	1.6	12
70	Excessive Fragmentary Myoclonus: What Do We Know?. Prague Medical Report, 2017, 118, 5-13.	0.8	7
71	Smoking Prevalence in Group of Central-European Patients with Narcolepsy-cataplexy, Narcolepsy without Cataplexy and Idiopathic Hypersomnia. Ceska A Slovenska Neurologie A Neurochirurgie, 2017, 80/113, 561-563.	0.1	1
72	The European Narcolepsy Network ( <scp>EU</scp> â€ <scp>NN</scp> ) database. Journal of Sleep Research, 2016, 25, 356-364.	3.2	47

#	Article	IF	CITATIONS
73	Distribution of HLA-DQB1 in Czech Patients with Central Hypersomnias. Archivum Immunologiae Et Therapiae Experimentalis, 2016, 64, 89-98.	2.3	3
74	Screening for REM sleep behavior disorder in the general population. Sleep Medicine, 2016, 24, 147.	1.6	29
75	Narcolepsy with cataplexy in patients aged over 60 years: a case-control study. Sleep Medicine, 2016, 26, 79-84.	1.6	20
76	Quantitative assessment of motor speech abnormalities in idiopathic rapid eye movement sleep behaviour disorder. Sleep Medicine, 2016, 19, 141-147.	1.6	68
77	Idiopathic hypersomnia. Sleep Medicine Reviews, 2016, 29, 23-33.	8.5	94
78	Decreased Perception of High Frequency Sound in Severe Obstructive Sleep Apnea. Physiological Research, 2016, 65, 959-967.	0.9	14
79	Smoking Prevalence and Its Clinical Correlations in Patients with Narcolepsy-cataplexy. Prague Medical Report, 2016, 117, 81-89.	0.8	2
80	The Course and Character of Sleepwalking in Adulthood: A Clinical and Polysomnographic Study. Behavioral Sleep Medicine, 2015, 13, 169-177.	2.1	20
81	Narcolepsy with and without cataplexy, idiopathic hypersomnia with and without long sleep time: a cluster analysis. Sleep Medicine, 2015, 16, 225-231.	1.6	48
82	Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: A multicenter study. Annals of Neurology, 2015, 77, 830-839.	5.3	248
83	Narcolepsy with cataplexy and Parkinson's disease. Case Report. Neuroendocrinology Letters, 2015, 36, 226-30.	0.2	2
84	Antidepressants substantially affect basic REM sleep characteristics in narcolepsy-cataplexy patients. Neuroendocrinology Letters, 2015, 36, 430-3.	0.2	3
85	Hippocampal but not amygdalar volume loss in narcolepsy with cataplexy. Neuroendocrinology Letters, 2015, 36, 682-8.	0.2	2
86	Brain activation sequences. Neuroendocrinology Letters, 2015, 36, 758-66.	0.2	0
87	Hypothalamo–pituitary–adrenal axis, glucose metabolism and <scp>TNF</scp> â€ <i>α</i> in narcolepsy. Journal of Sleep Research, 2014, 23, 425-431.	3.2	17
88	Comorbidity and medication in REM sleep behavior disorder. Neurology, 2014, 82, 1076-1079.	1.1	90
89	Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case–control study. Journal of Neurology, 2014, 261, 1112-1118.	3.6	90
90	Nightmares in narcolepsy: underinvestigated symptom?. Sleep Medicine, 2014, 15, 967-972.	1.6	42

#	Article	IF	CITATIONS
91	Adult NREM Parasomnia Associated with Lancinating Throat Pain. Journal of Clinical Sleep Medicine, 2014, 10, 925-926.	2.6	1
92	Neurologic Disorders. , 2014, , 241-247.		0
93	Clinical, polysomnographic and genomeâ€wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. Journal of Sleep Research, 2013, 22, 482-495.	3.2	182
94	Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Medicine, 2013, 14, 795-806.	1.6	209
95	Narcolepsy with cataplexy and parkinson's disease – A case report. Sleep Medicine, 2013, 14, e174-e175.	1.6	1
96	Narcolepsy: clinical differences and association with other sleep disorders in different age groups. Journal of Neurology, 2013, 260, 767-775.	3.6	49
97	Incomplete sleep paralysis as the first symptom of narcolepsy. Sleep Medicine, 2013, 14, 919-921.	1.6	8
98	ImmunoChip Study Implicates Antigen Presentation to T Cells in Narcolepsy. PLoS Genetics, 2013, 9, e1003270.	3.5	206
99	Family history of idiopathic REM behavior disorder. Neurology, 2013, 80, 2233-2235.	1.1	54
100	Narcolepsy and pregnancy: a retrospective <scp>E</scp> uropean evaluation of 249 pregnancies. Journal of Sleep Research, 2013, 22, 496-512.	3.2	54
101	Environmental risk factors for REM sleep behavior disorder. Neurology, 2012, 79, 428-434.	1.1	113
102	Diagnosis and management of central hypersomnias. Therapeutic Advances in Neurological Disorders, 2012, 5, 297-305.	3.5	19
103	European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. European Journal of Neurology, 2012, 19, 1385-1396.	3.3	131
104	Restless legs syndrome in Czech patients with multiple sclerosis: An epidemiological and genetic study. Sleep Medicine, 2012, 13, 848-851.	1.6	38
105	Severe sleep-related movement disorder induced by sertraline. Sleep Medicine, 2012, 13, 769-770.	1.6	10
106	CLINICAL DIFFERENCES BETWEEN CHILDHOOD AND ADULTHOOD NARCOLEPSY. Sleep Medicine, 2011, 12, S20.	1.6	0
107	Sleep disorders in Wilson's disease. European Journal of Neurology, 2011, 18, 184-190.	3.3	56
108	Clinical features of childhood narcolepsy. Can cataplexy be foretold?. European Journal of Paediatric Neurology, 2011, 15, 320-325.	1.6	29

#	Article	IF	CITATIONS
109	Sleep disturbances in untreated Parkinson's disease. Journal of Neurology, 2011, 258, 2254-2259.	3.6	40
110	Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1. PLoS Genetics, 2011, 7, e1002171.	3.5	163
111	Biochemical oxidative stress-related markers in patients with obstructive sleep apnea. Medical Science Monitor, 2011, 17, CR491-CR497.	1.1	47
112	THE INFLUENCE OF A SHORT DAYTIME NAP AND THE INFLUENCE OF ITS TIMING ON PSYCHOMOTOR EFFICIENCY. Neural Network World, 2011, 21, 539-550.	0.8	0
113	60 years of sleep medicine at the Department of Neurology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague. Prague Medical Report, 2011, 112, 236-43.	0.8	2
114	Effects of Ropinirole Prolonged-Release on Sleep Disturbances and Daytime Sleepiness in Parkinson Disease. Clinical Neuropharmacology, 2010, 33, 186-190.	0.7	36
115	Contribution of the Premotor Cortex to Consolidation of Motor Sequence Learning in Humans During Sleep. Journal of Neurophysiology, 2010, 104, 2603-2614.	1.8	85
116	Sodium oxybate is an effective and safe treatment for narcolepsy. Sleep Medicine, 2010, 11, 105-106.	1.6	29
117	Olfactory dysfunction in narcolepsy with and without cataplexy. Sleep Medicine, 2010, 11, 558-561.	1.6	18
118	Assessment of pregnancy outcomes in Czech and Slovak women with narcolepsy. Medical Science Monitor, 2010, 16, SR35-40.	1.1	16
119	Obesity accompanies narcolepsy with cataplexy but not narcolepsy without cataplexy. Neuroendocrinology Letters, 2010, 31, 631-4.	0.2	24
120	Replication of restless legs syndrome loci in three European populations. Journal of Medical Genetics, 2009, 46, 315-318.	3.2	78
121	Arousals in nocturnal groaning. Sleep Medicine, 2009, 10, 1051-1055.	1.6	20
122	Does age at the onset of narcolepsy influence the course and severity of the disease?. Sleep Medicine, 2009, 10, 967-972.	1.6	51
123	112 REDUCED VOLUME OF THE AMYGDALA IN NARCOLEPSY WITH CATAPLEXY – A STRUCTURAL MRI STUDY. Sleep Medicine, 2009, 10, S31.	1.6	0
124	Suggestive evidence for linkage for restless legs syndrome on chromosome 19p13. Neurogenetics, 2008, 9, 75-82.	1.4	61
125	PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nature Genetics, 2008, 40, 946-948.	21.4	252
126	A comparison of polysomnographic and actigraphic evaluation of periodic limb movements in sleep. Neurological Research, 2008, 30, 234-238.	1.3	23

#	Article	IF	CITATIONS
127	Advanced oxidation protein products in obstructive sleep apnea. Prague Medical Report, 2008, 109, 159-65.	0.8	4
128	Family-based association study of the restless legs syndrome loci 2 and 3 in a European population. Movement Disorders, 2007, 22, 207-212.	3.9	31
129	Clinical trials in restless legs syndrome—Recommendations of the European RLS Study Group (EURLSSG). Movement Disorders, 2007, 22 Suppl 18, S495-504.	3.9	15
130	Genetics of restless legs syndrome (RLS): State-of-the-art and future directions. Movement Disorders, 2007, 22, S449-S458.	3.9	73
131	Report of an EFNS task force on management of sleep disorders in neurologic disease (degenerative) Tj ETQq1 1	0. <u>78</u> 4314	rgBT /Over
132	Evening and morning plasma levels of protein S100B in patients with obstructive sleep apnea. Neuroendocrinology Letters, 2007, 28, 575-9.	0.2	6
133	EFNS guidelines on management of narcolepsy. European Journal of Neurology, 2006, 13, 1035-1048.	3.3	235
134	Cataplexy treated with escitalopramclinical experience. Neuroendocrinology Letters, 2006, 27, 174-6.	0.2	12
135	Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Medicine, 2005, 6, 415-421.	1.6	140
136	Dysexecutive syndrome following anterior thalamic ischemia in the dominant hemisphere. Journal of the Neurological Sciences, 2005, 229-230, 117-120.	0.6	9
137	Sleep and Fasciculations in Amyotrophic Lateral Sclerosis. Schlaf und Faszikulationen bei amyotropher Lateralsklerose. Somnologie, 2004, 8, 25-30.	1.5	5
138	Restless legs syndrome in 2004. Prague Medical Report, 2004, 105, 337-56.	0.8	6
139	Monitoring the Impact of Ventilation Abnormalities on the Occurrence of Interictal Epileptiform Patterns. Untersuchung eines Zusammenhangs von Atmungsstorungen mit dem Auftreten interiktaler epileptiformer Muster. Somnologie, 2003, 7, 97-100.	1.5	2
140	Cephalometric assessment of cranial abnormalities in patients with acromegaly. Journal of Cranio-Maxillo-Facial Surgery, 2003, 31, 80-87.	1.7	72
141	Management of restless legs syndrome by the partial D2-agonist terguride. Sleep Medicine, 2003, 4, 455-457.	1.6	11
142	Kleine-Levin syndrome. Neurology, 2002, 59, 1739-1745.	1.1	208
143	Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. International Clinical Psychopharmacology, 2002, 17, 9-17.	1.7	74
144	Increased REM Density in Narcolepsy-Cataplexy and the Polysymptomatic Form of Idiopathic Hypersomnia. Sleep, 2001, 24, 707-711.	1.1	30

#	Article	IF	CITATIONS
145	Electromagnetic field of mobile phones affects visual event related potential in patients with narcolepsy. Bioelectromagnetics, 2001, 22, 519-528.	1.6	30
146	Craniofacial abnormalities and their relevance for sleep apnoea syndrome aetiopathogenesis in acromegaly. European Journal of Endocrinology, 2001, 144, 491-497.	3.7	61
147	Electromagnetic field of mobile phones affects visual event related potential in patients with narcolepsy. Bioelectromagnetics, 2001, 22, 519-528.	1.6	1
148	Chapter 52 A contribution to pathophysiology of idiopathic hypersomnia. Supplements To Clinical Neurophysiology, 2000, 53, 366-370.	2.1	36
149	Prevalence of the sleep apnea syndrome in acromegaly population. Journal of Endocrinological Investigation, 2000, 23, 515-519.	3.3	81
150	Seizures in sleep apnea patients: occurrence and time distribution. SbornÃk Lékar̆ský, 2000, 101, 229-32.	0.2	10
151	Familial Aspects of Narcolepsy-Cataplexy in the Czech Republic. Sleep, 1997, 20, 1021-1026.	1.1	31
152	MESAM4 evaluated nocturnal respiration disturbances in myasthenia gravis. SbornÃk Lékar̆ský, 1996, 97, 97-102.	0.2	2
153	Effect of naloxone on diurnal polysomnographic manifestations of hypersomnia with sleep apnoea. Physiologia Bohemoslovaca, 1989, 38, 477-9.	0.1	1
154	DR2?NEGATIVE NARCOLEPSY. Lancet, The, 1986, 328, 684-685.	13.7	42
155	An Alternative to the Multiple Sleep Latency Test for Determining Sleepiness in Narcolepsy and Hypersomnia: Polygraphic Score of Sleepiness. Sleep, 1986, 9, 243-245.	1.1	41
156	Effects of Exercise on Serum Cortisol and Thyroid Hormones. Experimental and Clinical Endocrinology and Diabetes, 1983, 81, 308-314.	1.2	14
157	Idling for Decades: A European Study on Risk Factors Associated with the Delay Before a Narcolepsy Diagnosis. Nature and Science of Sleep, 0, Volume 14, 1031-1047.	2.7	18
158	Idiopathic Hypersomnia—A Dynamic Simulation Model. Frontiers in Neurology, 0, 13, .	2.4	1